Efficacy of ramosetron for prevention of postoperative nausea and vomiting in patients after total knee arthroplasty according to time of administration.

Efficacy of preemptive use of ramosetron for prevention of postoperative nausea and vomiting in patients after total knee arthroplasty: Comparison with postoperative use of ramosetron

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0005080

Enrollment

100

Registered

2020-06-02

Start date

2015-05-22

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : ramosetron 0.3mg was injected through intravenously 1 hour before surgery (immediate before leaving from ward to operating room) to preemptive group. ramosetron 0.3mg was injected through intra

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: the patients who underwent primary total knee arthroplasty due to end-stage osteoarthritis

Exclusion criteria

Exclusion criteria: contraindication to spinal anesthesia or conversion to general anesthesia due to failure of spinal anesthesia patients undergoing total knee arthroplasty, not due to osteoarthritis revision total knee arthroplasty patients undergoing bilateral total knee arthroplasty, 2nd surgery of staged total knee arthroplasty patients with an allergy to 5-HT3 receptor antagonists history of using streoid or other antiemetic drugs within 24 hours before surgery in the case of patient's medical condition which prevent using ramosetron

Design outcomes

Primary

Measure	Time frame
nausea;vomiting	—

Secondary

Measure	Time frame
rescue antiemetics;complication such as headache, dizziness, dorwsiness	—

Countries

Korea, Republic of

Contacts

Public Contacthyung jun park

Seoul Metropolitan Government Seoul National University Boramae Medical Center

Outcome results